Critical limb ischemia (CLI) imposes a major public health burden, resulting in high rates of death and disability. Thus far no medical therapy has been shown to ameliorate CLI. The goal of this proposal is to develop innovative therapeutic approaches for CLI with the use of endothelial progenitor cell (EPC) based therapies augmented by novel biomaterials-based approaches. These studies will investigate 3 novel bioactive peptide amphiphiles (PA) in combination with direct EPC injections or alone for repair ischemic limb tissue. One of the novels, bioactive motifs developed in our lab includes motifs that foster cell adhesion through a domain containing Arg-Gly-Asp-Ser (RGDS) we will extend preliminary data generated in our labs indicating that RGDS-presenting PA nanostructures enhance EPC function and investigate certain mechanisms responsible for these effects in models of critical limb ischemia. Another approach that we have explored is provision of an angiogenic signal with a vascular endothelial growth factor (VEGF) mimetic epitope. We will extend our preliminary in vitro and in vivo studies to evaluate the effect of VEGF-mimetic PA to improve perfusion in ischemic limb tissue. Abundant prior data from our lab has established that the morphogen Shh is activated post-natally in response to ischemia and that exogenous Shh can affect ischemic tissue repair. We have recently developed a novel, inject able liquid crystalline PA that provides sustained, local release of Shh protein and will investigate the use of this material to treat models of critical limb ischemia.
Critical limb ischemia (CLI) imposes a major public health burden, resulting in high rates of death and disability. Thus far no medical therapy has been shown to ameliorate CLI. The goal of this proposal is to develop innovative therapeutic approaches for CLI with the use of novel biomaterials-based approaches to enhance the effects of endothelial progenitor cell (EPC) based therapies.
|Cheng, Zhongjian; Verma, Suresh K; Losordo, Douglas W et al. (2017) Reprogrammed Human Endothelial Cells: A Novel Cell Source for Regenerative Vascular Medicine. Circ Res 120:756-758|
|Srikanth Garikipati, Venkata Naga; Kishore, Raj (2017) Young Hearts Run Free: Therapeutic Potential of Neonatal Human Cardiac Progenitor Cells Secretome. Circ Res 120:751-752|
|Verma, Suresh K; Garikipati, Venkata N S; Krishnamurthy, Prasanna et al. (2017) Interleukin-10 Inhibits Bone Marrow Fibroblast Progenitor Cell-Mediated Cardiac Fibrosis in Pressure-Overloaded Myocardium. Circulation 136:940-953|
|Kishore, Raj; Garikipati, Venkata Naga Srikanth; Gumpert, Anna (2016) Tiny Shuttles for Information Transfer: Exosomes in Cardiac Health and Disease. J Cardiovasc Transl Res 9:169-75|
|Morishita, Yoshihiro; Kobayashi, Koichi; Klyachko, Ekaterina et al. (2016) Wnt11 Gene Therapy with Adeno-associated Virus 9 Improves Recovery from Myocardial Infarction by Modulating the Inflammatory Response. Sci Rep 6:21705|
|Kishore, Raj; Khan, Mohsin (2016) More Than Tiny Sacks: Stem Cell Exosomes as Cell-Free Modality for Cardiac Repair. Circ Res 118:330-43|
|Jeyabal, Prince; Thandavarayan, Rajarajan A; Joladarashi, Darukeshwara et al. (2016) MicroRNA-9 inhibits hyperglycemia-induced pyroptosis in human ventricular cardiomyocytes by targeting ELAVL1. Biochem Biophys Res Commun 471:423-9|
|Cheng, Zhongjian; Garikipati, Venkata Naga Srikanth; Nickoloff, Emily et al. (2016) Restoration of Hydrogen Sulfide Production in Diabetic Mice Improves Reparative Function of Bone Marrow Cells. Circulation 134:1467-1483|
|Kishore, Raj; Krishnamurthy, Prasanna; Garikipati, Venkata Naga Srikanth et al. (2015) Interleukin-10 inhibits chronic angiotensin II-induced pathological autophagy. J Mol Cell Cardiol 89:203-13|
|Veliceasa, Dorina; Biyashev, Dauren; Qin, Gangjian et al. (2015) Therapeutic manipulation of angiogenesis with miR-27b. Vasc Cell 7:6|
Showing the most recent 10 out of 138 publications